RXRX insiders

18 insiders have filed at RXRX since 2023Q3: names, roles, reported stakes, and each person's buying and selling record from SEC Form 3/4/5 filings.

namerolereported stake% of companybuys (3y)sells (3y)
Borgeson BlakeDirector6.26M1.183%43 sells $7.7M
Bogue ZacharyDirector3.74M0.706%
Li Dean YDirector3.22M0.609%2 sells $396k
Khan NajatCEO And President2.26M0.427%3 sells $845k
Secora MichaelChief Financial Officer1.49M0.281%37 sells $5.9M
Taylor Ben RChief Financial Officer1.18M0.223%3 sells $158k
Hallett DavidChief Scientific Officer1.10M0.207%
Gibson ChristopherDirector906.6k0.171%85 sells $19.7M
Marriott TinaPresident And COO506.9k0.096%20 sells $857k
Mauro David JChief Medical Officer225.4k0.043%
Dar ZavainDirector142.3k0.027%1 sells $181k
Virani ShafiqueChief Business Officer136.7k0.026%10 sells $2.3M
Michor FranziskaDirector127.1k0.024%
Hershberg RobertDirector73.7k0.014%
Burrell Terry-AnnDirector71.3k0.013%5 sells $1.4M
Chavez R. MartinDirector60.1k0.011%
Bumpus NamandjeDirector47.6k<0.01%
Sun Elaine DDirector47.6k<0.01%

Full register at boothcheck.com/insiders/RXRX. Stakes are the newest reported Form 3/4/5 balances (they update only when insiders file). Sales counted include pre-scheduled plan sales, labeled. A filed record, not a forecast. Nothing here is investment advice.

RXRX institutional holders · RXRX research report